- Market Capitalization, $K 61,000
- Shares Outstanding, K 16,442
- Annual Sales, $ 0 K
- Annual Income, $ -17,250 K
- 60-Month Beta 1.45
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 3.55
|Period||Period Low||Period High||Performance|
| || |
+0.90 (+32.03%)since 11/05/19
| || |
+0.46 (+14.15%)since 09/05/19
| || |
-0.31 (-7.71%)since 12/04/18
As of late, it has definitely been a great time to be an investor Eyenovia, Inc. (EYEN).
Eyenovia, Inc. (EYEN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
There is an alarming increase in the frequency of eye-related diseases, particularly in developed countries, which in turn is expected to drive the growth of the global retinal drugs market. There are...
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced...
Canopy Growth (CGC) acquires a number of European companies to expand its production base across a region that promises great opportunities.
Applied Materials' (AMAT) technology leadership position and strong product line in Display and Services are likely to reflect on fiscal fourth-quarter results.
A series of acquisitions is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal second quarter.
Overstock's (OSTK) third-quarter results are likely to reflect strength across retail and blockchain businesses.
Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.
Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress, when it reports Q3 results.